Special Melanoma Scenarios

*Cutaneous Melanoma*

cell sub-lines of mouse melanoma (B16BL6 and PG19). Melanoma Research. 2001;**11**(2):197-201

Sinibaldi-Vallebona P, et al. Progesterone and melanoma cells: An old story suspended between life and death. Journal of Steroids and Hormonal Science. 2015;**S13**:158. DOI:

10.4172/2157-7536.1000158

[42] Miller A, Fulcher A, Dock P, Ramaraj P. Biochemical basis of

[43] Schadendorf D, Möller A,

Singh RK, Reich R, Bar-Eli M.

1993;**151**(5):2667-2675

protection by progesterone in melanoma based on curcumin pre-treatment of human melanoma cell models. In: Endo2018Home; 2018. Available from: http://www.abstractsonline.com/ pp8/#!/4482/presentation/7469

Algermissen B, Worm M, Sticherling M, Czarnetzki BM. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. Journal of Immunology.

[44] Luca M, Huang S, Gershenwald JE,

Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. The American Journal of Pathology. 1997;**151**(4):1105-1113

[45] Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Research. 1994;**54**(12):3242-3247

[46] Häggström M. Reference ranges for estradiol, progesterone, luteinizing hormone and follicle-stimulating hormone during the menstrual cycle. WikiJournal of Medicine. 2014;**1**(1):1.

DOI: 10.15347/wjm/2014.001

[35] Ramaraj P, Cox JL. In vitro effect of sex steroids on mouse melanoma (B16F10) cell growth. CellBio. 2014;**3**: 60-71. DOI: 10.4236/cellbio.2014.32007

[36] Ramaraj P, Cox JL. In vitro effect of progesterone on human melanoma (BLM) cell growth. International Journal of Clinical and Experimental Medicine. 2014;**7**(11):3941-3953, PMID: 25550902; PMCID: PMC4276160

[37] Seglen PO, Gordon PB.

[38] Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nature Medicine.

[39] Leder DC, Brown JR, Ramaraj P. In vitro rescue and recovery studies of human melanoma (BLM) cell growth, adhesion and migration functions after treatment with progesterone. International Journal of Clinical and Experimental Medicine. 2015;**8**(8):12275-12285. PMID: 26550137 [PubMed] PMCID: PMC4612822

[40] Fang X, Zhang X, Zhou M, Li J. Effects of progesterone on the growth regulation in classical progesterone receptor-negative malignant melanoma cells. Journal of Huazhong University of Science and Technology. Medical Sciences. 2010;**30**(2):231-234. DOI:

10.1007/s 11596-010-0220-3

[41] Moroni G, Gaziano R, Bue C, Agostini M, Perno CF,

2009;**15**(3):267-276

3-Methyladenine: Specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proceedings of the National Academy of Sciences of the United States of America. 1982;**79**:1889-1892

**52**

**55**

**Chapter 4**

**Abstract**

syndrome, vemurafenib

**1. Introduction**

Melanoma and Pregnancy: Risks,

Currently, the term "melanoma associated with pregnancy" is used, implying the inclusion of all clinical observations of melanoma diagnosis during pregnancy and in the first 2 years after delivery. The management of pregnant women with newly diagnosed melanoma is likewise controversial, especially with regard to the management of women with an advanced melanoma. Thrombotic complications are the most common form of paraneoplastic syndrome, which largely determines the prognosis of the disease. The presented chapter is intended to familiarize practical physicians with the complexities that arise in the management of pregnant women with a developing metastatic disease, with questions of the progression of the disease during pregnancy, with the emergence of severe paraneoplastic complications involving secondary thrombophilia, amaranthine endocarditis, and widespread arterial thrombosis. The possibility of using modern antitumor drugs (Zelboraf) is shown. It is emphasized that in the management of such patients, the need for an effective team of specialists of various profiles is especially high: oncologists, obstetrician-gynecologists, surgeons, hematologists, anesthesiologist-

resuscitators, and US and magnetic resonance imaging (MRI) diagnostics.

**Keywords:** melanoma, pregnancy, secondary thrombophilia, paraneoplastic

Melanoma of the skin (*lat. —melanoma, melanoma malignum*) is a malignant tumor that results from neoplastic transformation of melanocytes—cells that produce various variations of melanin pigment [1]. In recent years, there has been an increase in the incidence of skin melanoma in Russia. Between 1998 and 2008, the incidence rate in the Russian Federation was 38.17%, and the standardized morbidity rate rose from 4.04 to 5.46 per 100,000 population. In 2008, the number of new cases of melanoma in the Russian Federation was 7744 people. Mortality from melanoma in the Russian Federation in 2008 was 3159 people and a standardized death rate of 2.23 people per 100,000 population [2]. Approximately one-third of women diagnosed with melanoma are of childbearing age, and a 2015 Swedish population-based cancer registry study found that melanoma was the most common malignancy in pregnancy [3]. Melanoma is a significant proportion of all tumors diagnosed during pregnancy, and this figure is up to 25% among all tumor diseases during gestation. There is continuing controversy concerning the

Current, and Forecast

*Ignatko Irina Vladimirovna and* 

*Strizhakov Alexander Nikolaevich*
